Secondary biomarker analysis of ENZAMET (492 of 1,125 men with metastatic hormone-sensitive prostate cancer): an AI pathology classifier modified enzalutamide benefit (interaction P=0.014); HR 0.50 if APIC-negative vs 1.04 if APIC-positive.
RCTn = 492
Medina et al. AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial